More Than a Message: Patients have a strong preference for how they learn about their #cancer diagnosis. A survey found that 75% of patients prefer to hear the news from a clinician, not a patient portal.

Results showed portal preference was more common among men.

The October issue is out now! Highlights include a feature on the #healthcare and practice issues at stake in the U.S. midterms, collaboration between #hematology and #cardiology in the management of AL #amyloidosis, and more. Check out the full lineup 👉 https://ow.ly/mJwE50ZV3r3

Recent research indicates that a higher ratio of #vonWillebrand factor to ADAMTS13 is associated with large white matter hyperintensities on brain MRI, a finding that potentially implicates an effect of the VWF-ADAMTS13 axis on #cerebrovascular disease: https://ow.ly/66gL50ZUv6h

The $9 Trillion Tab: National #healthcare spending is on the rise. Federal data show that healthcare spending is set to reach $9 trillion by 2034.

Retail prescription drugs, #Medicaid overhauls, and escalating #Medicare enrollment are a few factors driving the spending growth.

55-month follow-up from the phase III TRIANGLE trial confirms that adding #ibrutinib to immunochemotherapy produces strong rates of failure-free survival and OS in adults with #MCL, at 82% and 88%, respectively, indicating the treatment could be a new SOC: https://ow.ly/BtHJ50ZT4ua

Complement activation. Chronic inflammation. Immune-meditated pathways across cytopenias.

Tomorrow, join a free webinar to learn how targeting shared immune mechanisms may improve outcomes in #ITP, #wAIHA, and beyond.

📅 Sept 30 · 10 AM EDT
Register at👇
https://ow.ly/UmIN50ZSEs1

In treating R/R #MMsm, BCMA-targeted CAR-T therapy prior to a bispecific antibody led to greater OS rates (79% vs. 63%) than did a bispecific antibody followed by CAR-T therapy, suggesting that such a sequencing strategy could improve survival probability: https://ow.ly/Q2X450ZRwY3

Complement activation. Chronic inflammation. Shared mechanisms across cytopenias.

In a free webinar, learn how a pathway-based approach can sharpen your clinical management of #ITP, #wAIHA, and beyond.

📅 Sept 30 · 10 AM EDT
Register at 👇
https://ow.ly/ck1s50ZPIfv

#Hematology

In older patients with FLT3-mutated #AML, the addition of #quizartinib to intensive chemotherapy significantly improved overall survival compared with chemotherapy alone at a rate of 47% vs. 25%, in addition to reducing relapse risk: https://ow.ly/4nux50ZOt4m

Calling all #hematology voices! 🩸

ASH Clinical News is looking for associate editors to join the team, and we want YOU. Pitch stories, write columns, and help shape coverage of the studies that matter most in your field.

Apply by September 18 👉 https://ow.ly/U7zE50ZO4PJ

All-oral decitabine-cedazuridine plus venetoclax was found to be efficacious in patients with newly diagnosed acute myeloid leukemia #AML who are 75+ years or ineligible for intensive chemo, producing a CR in 47%, and did not cause drug interactions: https://ow.ly/YNlZ50ZLCSS

A #ferritin threshold of 30 µg/L for #IronDeficiency screening during the second and third trimesters of pregnancy is cost effective, according to new research, generating 25.14 QALYs at a cost of $204 ,300, an improved rate compared with no screening: https://ow.ly/SXO050ZLC1z

The newest issue is out now! Highlights of the September issue include insights into pain management for #SCD beyond vaso-occlusive crises, a challenging case of a young patient with R/R ALL with CNS involvement, and more. Check out the full issue 👉 https://ow.ly/FyzL50ZKL5x

📢 Your voice belongs in #hematology

ASH Clinical News is seeking new associate editors for 2027-2029 terms. Pitch stories, write columns, & help shape coverage of the studies that matter most in your field.

Apply by September 18 for best consideration👉 https://ow.ly/iRNx50ZJzPB
#HemeSky

Mim8 (denecimig) was effective in preventing bleeding in patients with #hemophilia A, producing mean ABRs of 0.57 and 0.20 in patients receiving weekly and monthly Mim8 injections, respectively, compared with 15.76 in those receiving on-demand treatment: https://ow.ly/i3Uw50ZIrP8
#HemeSky

"Without research today, there will be no additional cures; it is critical to saving lives."
With federal research funding under attack, the American Society of Hematology is taking a stand in the #Fight4Hematology. Read the story behind this important initiative: https://ow.ly/XlgX50ZHu1F

Findings from a small study of patients with primary or secondary CNS #lymphoma have shown that #glofitamab can cross the blood-brain barrier and induce remission within just a few weeks of administration, producing an ORR of 87.5% among the full cohort: https://ow.ly/FYWq50ZHqob
#HemeSky